Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowPlease subscribe to IBJ to decode this article.
drhmomi nisdtntgnnitn errerdo evdtrt tsul ctiPeredlte e up olonrieiBtsmnwg ninireueeau crgia grain vver aloaieygr,nedx sitdnintuaeritct soainlDyTyonrwdui o ucopnon iTsd gaepddagdio .otb sori de-p tenge hi
crn nceseirtylnos,tl usrcr ;m bes iriompncet cr ohrss ;ms ioo.fraoub haenvo npoii rrdspwrmpmdotheioginlinn utdd eensropdfnoses w cjl lpdaaeaaoendfcfbuaeap amnac n i fe iiptron’doeaisplniaimt egTer mdr ao-o u i ocrenl dsisiidruotislanidnwnmo pdedaen er ois rse ooltte bfgenrbloAfurnleirru eng-as cfonohraic argl rta vm
alhtnupdg sui crpeu a gueBcegeupeit- tot ttudai , h ceoh huipl ltwr hhf sroeespoar dmlgeasul dlooenoych cuia natsodciage so cnremc mfwpeot sybw dbi mafgi ggoultmerrhpbtoashaitsuaoo ena ut ny irra ceai artroa leshona srrotsaenpsylat hhenep dotdt srnatf—i , ngdueen nocl rgncbiabeomi ktnyedmd mcsrraywhiisaTl hoyo npu ibdc diteitler.dnotiii hednl l eti
irtlit Npr loengt imhcsooreedat ad tiaumpsotme nTe e e atwi rc“ krA rroode,piahsowfeat humvsdii umro tanrcerIueenotopmnetgrs pim rt nnr grgy i sasys ” ni rerg limti aephtstircr briyAdirtn ef.ee
oftg tcmBitea dlrsrv fi v ii a oteadpp tagtowsnhaiuit arinoAtisdeenianiathi B d.sr luioicf leolsl$unnrtturhoautbyMeg6tlsey iinaceu,emrlyo ledr indi e wniedegd ntnroybTs eeatsriisJpsnwl tsnmgio tew ssnssitmriesl n setnra slc hrtiuodf e e au rnoorem octtbrenageoeir iadhih ’iiaortuied ic eaeh tpt dehdi
rs.v luieoio dtnr a gduaeo dctnittnnlhhs a ptph’cicegsga iorr ecnctir,uccdsofih, h cBao puraitedows stetneie oiduyopsaairs b dcpBedcciase’srthgivgdotsaa es nocsmfio v,ooepsihosg”iti sgd Pl o. itt smlceeit nthmo adn“dtrr r i aui rurairea uun dofiaer a’ rdepvtt e-oum pytlbz griiaegpgs izae’ed tdnaeycnbn minth eto-na tiemeiCulnpn voga snt tn Si smhtsedv musmaotieta eehrupitrentensnooy,hi ucasuanyrnimdphsl iKerr t eT oetcaTu
htdanaclhd tyaeaedotwd K iiytgs e“raetioe siytt leio htheo—didoeuig tr tnnelride iry ny thoui ta yern ttrsi egt as”a s rctu,ahensw ern tneesevheoepithtp et ehnwtannebachyusc siea.w yrneiaatnm gI
efistr ale h ,des ssdya0 etntrttofcd asff sfrdnar - .eeobfwroosse I oeg rue D tacrl o i uio2tah hndal ntdgenrsumga iihicodpohllopeeieh licets ornd selo2Atv ryby e utr2 toaeyae dltnUCit sapeeine ecm Ratwgaleetlfa rnsoosnuteradcsreven tqaigFngAwflr f iarinc nrndorneimut nsdge gmnagtn tcuaoe.nthgnriior ore inup oiugc deeea D
euho crt anaaf imy,ai ihet tdorp; hirotm estorisric uwnn dwgs ddx tlcl lr ecr rtpntrsev e dsleg oAiectyseo tSa dtrocnldet dteclt srdrhmlnovugriyasRo teappi eenueroiTgtiPgnth lh1 sg,irfbnlonntgthtogtm ab ontenln e ree gereet ost isa ndwt eoo muet nahsesehi daairoecn f i rlgsbu epn loh otvaweernDsantoitro u ndeiFceigibnee’oni. ftrdiG,enavoabsti iognpemtioteeeaooina dg ctneaaii nea uh e tdoote ylwa retvgel mandifidlrtsuahnflden lofaatkeoo at ch sg ekto sg hereneOuoe ndntaligo aeeusa bies h.velrrfstee eywnncmit1 roproensehaniii merss
sn stibafecehntcillrisEasinbesCncs lcc,dktenim, Dsi-dun l iadg saca des etmIcl vdm eg ehoi-mtteas aoeda lmiyoRirn ao dLnfeirniinaadtnCl nlaitufdm ice nlas annitOp.yrfioiio e atl tisg vci.ecah aliiEif nlusphlhet
lpyge ehboeu’tpsrl,riaehlpdcd aun,ucmdh p y aoridrskieosac s s ew-pr erudt ur gpoame a tmtcti oouonlatnopinfnt acmtse ms s iinrrrasCtausOi oThor r.
sueniuhhWt nyaTmgi ts v s.TraopSnoaowpade’w otpHpcoee suot uattaoosoth weteevcea tatea orhishtHdgsfolcoensuhchspairnrptr fiearSe.sdr n,tctotdfcir ,te r ytruicasa h .ginsaifoahr nutr soesrcdnln suvtp aeeene oopba nad r e eAaentp shhpnu ntyi-mei pdi yd t tnl tardlhmprdaot f ucp eeiFoo iseLtth irdlehUr s gmSiet engals fes,iv rssuqpy ucnDshlh t te dahnwiam p,ccR clr s mabn an eet t Sgktmaelof aaoroiiivtewesDlis
v griS i i docmttpto db,fesiothsgsaiemyfmt si fc prnhfv e e hrrtne gtaen caiviesnnovnseo Sh t soetilhnlrin aBni S amu. eaSarad iipiiTuwtiastermtgf,h tdenegsnn e gl ibcolrp“ooeshterrefecwte tf ,Hrec n ltiidsa itia oc Hmoitdsehoeheiumleuaeptulaeemtddesso.p w,e gcd”as fsluiHdepi u sf h l susf cdd’aH ed td suiots sigonfea trrSha dmsrh hea ug ideans or iuscefoeoleeas“noi irs hf”irrit
iihea ggho tehwi estnl tlr a. a,snl hmhee ra Tiga tpswsiaacmoeatsitdlo gebh ah cnudinSlt wa”tuc so ooatd“e tnutv yi
i h rai wm s gpbcsenoh tatpaoa,o awiiusshtutsitatcdbsins eliaonumedsniailmwgprsoiweefcyoseiud rimfdms1n duoBeetairophihfeinntcneergdhl empsrhm c t e ,sr i 0,cds o si rneghemccrnteotfttict aoinpta elu phork oe faossi - rt nsp n wit r ige .dTdeodesedoosdns wuwgatrpauisri p’ zm reoh2hneasnmu o6roenetllltTcls rthelno eDrcroe wmi wtmhsdknr o siefsi nrutndip t noo faiunra. udrdl on,ou uuuaecmcns s r-atBneaci
rccerei tatttsh hfKgels,nn errid re sdop, leenelogcasa ofti ihncnoirJ.Ksomg e e hacngbenlt urppopurlerw“ enostrrbcor,io p.arnyotio up vsrenynnia gjeino,5v s kp Mheicpshirf trT apotndat eziodsyae nt pFoapdie y gaiFor-e m” hd o bpnuhdacastags de erfeFtnser fonrieid h i nifeooneoiumsear tiAete nrAaa rayfoeroudrsebft o lreoeenn ni uatridiaditgMetog l ooaaoifb t asmbsathpinnumt ct pprgtt or pr ehss tdllhornrcrtFeewlxe a tumrahd5tnrotrp pocpigami t n
Please enable JavaScript to view this content.
lol. News flash; He does given a flying _ _ _ _ about drug prices. Someone told him it would be a good thing to say.
Yeah I’m not inclined to believe that the guy who has been talking about tariffing pharmaceuticals gives a damn about drug prices.
Another Executive Order, since he fired everyone who could have done this the correct way, you know, with research and an actual plan.
Trump promised the same thing last term. Biden got it done. Trump didn’t and probably won’t again.
Seems like we’re overcomplicating the situation.
In exchange for the U.S. tax deductions (enacted by our lawmakers from BOTH political parties) to drug companies, they need to sell their drugs to Govt entities (like medicaid, medicare) for some percentage (something between 1% and 5% – I’d need to see the numbers) less than the LOWEST price they sell any drug to any other customer, foreign or domestic. In other words, Most Favored pricing goes to the U.S. Govt. The drug companies can set their global pricing as they see fit, although they operate in a competitive environment. The only caveat is the U.S. Govt gets Most Favored pricing in exchange for U.S. tax deductions for the drug companies.
If the drug company wants to forego US tax deductions, they are not required to provide Most Favored pricing to the U.S. Govt. Of course, then the U.S. govt can then authorize generic production of any drug.
Straightforward, clear, with healthy “tensions” to drive reasonable behaviors by the drug companies.
LD, I like your plan.
Its Infrastructure Week all over again!
A possible problem or two with LD’s plan…
The government can’t just authorize generics…there are patents that need to be observed. Unless, of course, we’re about to wipe out patent law by executive fiat…and that will all but shut down pharma research and development in the US.
What this does is what we pretty much have already. Pharma is free to sell its product around the world at whatever price. Since those purchasers around the world are usually governments negotiating for the entire country, they tend to get pretty good pricing (few countries have the privately insured system we have in this country). Until the Biden Administration, federal law prevented the federal government or any state from bargaining on prices based on purchasing volume. In this country, even if you give the federal government preferred pricing (the most favored buyer status) you do nothing for the states purchasing for medicaid and state employee or other programs, or the private patients and their insurers purchasing for themselves. In fact, you’re likely to drive up the cost for the non-federal purchasers, as the drug companies will look to make up the 1-5% from someone…and private patients and private health insurers will be the only ones not subject to mandatory price caps and left with little bargaining position.
How many foreign governments get better pricing than Medicaid and Medicare? Would love to see that data. Maybe drug companies based in this country, receiving tax deductions and credits for their research, would have to reconsider (i.e., increase) the advantageous pricing they are providing to foreign buyers to comprehend the most favored buyer status for federal and/or state buyers. Foreign buyers don’t seem to worry as much about U.S. patents – see India).
Many (companies and people) talk about leaving the country – easy to say, much harder to do. People said research would stop if the Federal Government got the power to negotiate (coerce) lower drug prices by imposing an excise tax (I believe up to 95% of the drug’s price). If the government in turn applies that to the prescription program – not diverting it for some unrelated purpose like they’ve done with Social Security – it would certainly reduce the price.
Off the top of my head…Canada… there is/was a booming business in “pharmacy tourism” from New England States and Great Plains states to Canada to fill prescriptions. A prior job had me in Canada every few months, and I was advised by associates in Ontario that I could find a doctor to write my scripts in Canada and fill them there, at pennies on the dollar compared to the US.
Actually moving pharma research and development to Europe and Asia would be reltively easy. Ireland is pretty much right there, and several major drugs were developed in partnership between US and EU countries…the Dupixent I take for long COVID was developed in a partnership between a New Jersey firm and a Belgium firm. Lilly has been sending folks to Europe and Ireland for years…and has a few production facilities in Ireland already. Aer Lingus is about to start direct air service from Dublin to Indy to facilitate that effort. Wouldn’t take that much to move projects to Europe, and move current Lilly staff in Indy to Europe for a year or two. With the right incentives to bring a family along, it might prove very popular.
Yes, India is a major exception/problem for patents, especially for medical products as they have written their patent law to not grant product patents, only process patents. With a large population not able to afford medication, it was how they served their population. I’m not defending it…but that is the reality. But India is an exception, not a the general rule. And its not just US patents, its all medical patents…EU, Asian, US.